Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04617652
Other study ID # R142
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date August 1, 2020
Est. completion date April 1, 2021

Study information

Verified date August 2021
Source Fayoum University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Tracheal extubation is a critical event in the anaesthetic management of patients undergoing general anaesthesia with endotracheal intubation for elective procedures. It the state of art to provide suitable conditions for smooth extubation and avoid coughing, bucking, straining and/or laryngospasm. Several methods have been described to provide a smooth extubation, including the use of remifentanil infusion, dexmedetomidine or fentanyl. Because of its anti-inflammatory and analgesic effects and lack of respiratory depressant actions, magnesium sulphate could be an attractive alternative.


Description:

A written informed consent will be obtained from all the patients. On arrival to the preparation room intravenous cannula will be inserted, no sedation will be given. In the operating theater standard monitors, non-invasive blood pressure, oxygen saturation and electrocardiogram will be applied before induction of anesthesia, capnography after induction of anesthesia and baseline heart rate (HR), mean arterial blood pressure (MAP) and oxygen saturation (SpO2 ) will be recorded. All patients in both groups will receive standardized anesthetic technique in the form of intravenous (i.v.) propofol 2 mg/kg, i.v. fentanyl 1-2 lg/kg and atracurium 0.5 mg/kg to facilitate endo-tracheal intubation, mechanical ventilation will be adjusted to keep end tidal carbon dioxide (EtCO2) between 30 and 35 mmHg, and all drugs will be based on ideal body weight. Isoflurane 1% in 50% oxygen and air, and 0.15 mg/kg atracurium every 20 min will be given for maintenance of anesthesia. Intraoperative HR, MAP, EtCO2 and SpO2 values will be recorded at 5- minute intervals till the end of operation. HR and MAP will be maintained within ±20% of the baseline values. Hypotension (defined as MAP < 20% of the baseline value) will be treated by a bolus of 200 ml Ringer's solution if not responding increments of 3-9 mg ephedrine will be given. Hypertension (defined as MAP > 20% of the baseline value) and/or tachycardia (defined as HR > 20% of the baseline value) a supplemental dose (25-50 µg) fentanyl will be given or increasing concentration of isoflurane. Bradycardia (HR < 50 beat per minute) persisting for >2 min will be treated with atropine, 0.4 mg i.v. boluses. Intra-operatively i.v. ondansetron, 4 mg (Zofran, GlaxoSmithKline) will be given for prevention of postoperative nausea and vomiting. After induction of anaesthesia patients will be divided into 2 groups: group C (control group) n= 30 patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour. Group M (magnesium group n=30 patients) will receive 1 gm of magnesium in 10 ml over 5 minutes then infusion of 1 gm in 50 ml over one hour. By the end of surgery isoflurane will be discontinued and the residual neuromuscular block will be antagonized with neostigmine 0.05 mg/kg, given with atropine 0.02 mg/kg, the endotracheal tube will be removed after return of spontaneous breathing, and the patient will obey commands in semi-sitting position, then the patient will be transferred to the post-anesthesia care unit (PACU)


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date April 1, 2021
Est. primary completion date February 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Elective surgeries that need endotracheal intubation. - Duration of surgery 1-3 hours - ASA ?-? Exclusion Criteria: - Refusal of patients. - Patients with hypersensitivity to the study drug. - Patients with cardiac disorders, bundle branch block, hart block - Neuromuscular disease, calcium channel blocker medication or hypermagnesemia

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Magnesium sulfate
Patients will receive 1 gm of magnesium in 10 ml over 5 minutes then infusion of 1 gm in 50 ml over one hour.
Normal saline
Patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour.

Locations

Country Name City State
Egypt Fayoum University hospital Fayoum Fayoum, Madinat Al Fayyum, Faiyum Governorate, Egypt

Sponsors (1)

Lead Sponsor Collaborator
Fayoum University Hospital

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary smoothness of extubation Smoothness of extubation Grade
No coughing on endotracheal tube
Coughing on the tube
Vomiting
Laryngospasm
Procedure (At time of extubation)
Secondary sedation score Ramsey sedation score (RSS): 1 - Anxious, agitated or restless; 2 - Cooperative and oriented; 3 - Responsive to commands; 4 - Asleep, but response to light glabellar tap or loud auditory; 5 - Asleep, sluggish response to glabellar tab or auditory response; and 6 - Asleep, no response 1 hrs after extubation
Secondary sedation score Ramsey sedation score (RSS): 1 - Anxious, agitated or restless; 2 - Cooperative and oriented; 3 - Responsive to commands; 4 - Asleep, but response to light glabellar tap or loud auditory; 5 - Asleep, sluggish response to glabellar tab or auditory response; and 6 - Asleep, no response 1 hour after extubation
Secondary heart rate hemodynamic parameters 5 minutes before induction of anathesia
Secondary Mean arterial blood pressure hemodynamic parameters 5 minutes before induction of anathesia
Secondary SpO2 hemodynamic parameters 5 minutes before induction of anathesia
Secondary EtCO2 hemodynamic parameters 5 minutes before induction of anathesia
Secondary heart rate hemodynamic parameters 5 minutes after induction of anathesia
Secondary Mean arterial blood pressure hemodynamic parameters 5 minutes after induction of anathesia
Secondary SpO2 hemodynamic parameters 5 minutes after induction of anathesia
Secondary EtCO2 hemodynamic parameters 5 minutes after induction of anathesia
Secondary heart rate hemodynamic parameters 10 minutes after induction of anathesia
Secondary Mean arterial blood pressure hemodynamic parameters 10 minutes after induction of anathesia
Secondary SpO2 hemodynamic parameters 10 minutes after induction of anathesia
Secondary EtCO2 hemodynamic parameters 10 minutes after induction of anathesia
Secondary heart rate hemodynamic parameters 15 minutes after induction of anathesia
Secondary Mean arterial blood pressure hemodynamic parameters 15 minutes after induction of anathesia
Secondary SpO2 hemodynamic parameters 15 minutes after induction of anathesia
Secondary EtCO2 hemodynamic parameters 15 minutes after induction of anathesia
Secondary heart rate hemodynamic parameters 20 minutes after induction of anathesia
Secondary Mean arterial blood pressure hemodynamic parameters 20 minutes after induction of anathesia
Secondary SpO2 hemodynamic parameters 20 minutes after induction of anathesia
Secondary EtCO2 hemodynamic parameters 20 minutes after induction of anathesia
Secondary visual analogue scale (VAS) pain score the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain 4 hours after extubation
Secondary visual analogue scale (VAS) pain score the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain 6 hours after extubation
Secondary The duration of surgery time needed to perform surgery 5 minutes after extubation
Secondary Intraoperative fentanyl needed The amount of Fentanyl given intraoperative as fentanyl will be given when either heart rate or NIBP(Non-Invasive Blood Pressure) report an increase by more than 20% of the basal records 5 minutes after extubation
Secondary The cumulative opioids (morphine) consumption The total amount of opioids received post operative 6 hours after surgery
See also
  Status Clinical Trial Phase
Completed NCT04365686 - Smooth Extubation With Ketofol for Induction of General Anesthesia in Laparoscopic Drilling of Polycystic Ovary Phase 4